News
VKTX
38.28
-18.03%
-8.42
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), TransCode Therapeutics (RNAZ)
TipRanks · 1h ago
BUZZ-U.S. STOCKS ON THE MOVE-BioAge Labs, Expedia, Citizens Financial Group
Reuters · 17h ago
What's Going On With Viking Therapeutics Stock On Wednesday?
Benzinga · 17h ago
MasterCard boosts dividend, Jabil reports Q1 beat: Morning Buzz
TipRanks · 18h ago
Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers
Seeking Alpha · 20h ago
Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.
Dow Jones · 20h ago
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
Barron‘s · 20h ago
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Benzinga · 20h ago
Merck’s $2B GLP-1 deal highlights ‘market hunger,’ says H.C. Wainwright
TipRanks · 20h ago
SHARES OF STRUCTURE THERAPEUTICS FALL 7.2%, VIKING THERAPEUTICS FALL 7.9%
Reuters · 21h ago
BUZZ-Shares of some obesity drug developers fall after Merck signs $2 bln deal to develop oral obesity drug
Reuters · 21h ago
Viking Therapeutics lower after Merck signs pact with Hansoh for GLP-1 drug
TipRanks · 22h ago
S&P 500 Futures Up In Premarket Trading; Silgan Holdings, PennyMac Finl Svcs Lead
Barron‘s · 23h ago
Viking Therapeutics Stock Slides After Merck Strikes GLP-1 Deal With Chinese Biopharma, Retail Unperturbed
Barchart · 1d ago
Viking Therapeutics: Caution Ahead Of Novo's CagriSema Readout (Rating Downgrade)
Seeking Alpha · 2d ago
Weekly Report: what happened at VKTX last week (1209-1213)?
Weekly Report · 3d ago
Altimmune 2025: Redefining Obesity And MASH Treatment
Seeking Alpha · 3d ago
Viking Therapeutics, Inc. (VKTX) Stock Moves -1.75%: What You Should Know
NASDAQ · 5d ago
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Benzinga · 5d ago
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Barron‘s · 5d ago
More
Webull provides a variety of real-time VKTX stock news. You can receive the latest news about Viking Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.